The Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor for Patients with Urothelial Carcinoma of the Bladder Following Radical Cystectomy by Zattoni, Fabio
       
 
 
Sede Amministrativa: Università degli Studi di Padova 
 
Dipartimento di Scienze Chirurgiche Oncologiche e Gastoenterologche 
___________________________________________________________________________________ 
 
Corso di Dottorato di Ricerca in: Oncologia Clinica e Sperimentale e Immunologia 
XXXI CICLO 
 
 
The Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor 
for Patients with Urothelial Carcinoma of the Bladder 
Following Radical Cystectomy 
 
 
 
 
 
Coordinatore: Ch.mo Prof. Paola Zanovello 
Supervisore: Ch.mo Prof. Giacomo Novara 
 
        
 
Dottorando: dr. Fabio Zattoni 
 
2 
 
  
3 
 
 
 
 
 
 
Index 
 
Abstract ............................................................................................................................................................ 5 
Introduction ..................................................................................................................................................... 7 
Aim of the study ............................................................................................................................................... 8 
Material and Methods ..................................................................................................................................... 9 
Results ............................................................................................................................................................. 11 
Discussion ....................................................................................................................................................... 27 
Conclusions .................................................................................................................................................... 32 
Bibliography ................................................................................................................................................... 33 
 
 
 
 
 
  
4 
 
  
5 
 
Abstract 
Introduction: Pre-treatment neutrophil-to-lymphocyte ratio (NLR) has been associated with 
adverse pathology or survival in a variety of malignancies, including urothelial carcinoma of the 
bladder (UCB) treated with radical cystectomy (RC). Whether the prognostic value of NLR is 
retained, or even increased, when measured postoperatively remains not well studied. In this 
study, we evaluated the association of preoperative and postoperative NLR with oncological 
outcomes following RC. 
Methods: 132 consecutive patients with UCB treated with open RC were analyzed. NLR was 
analyzed both as a continuous variable and as a categorical variable using a cut-off of 2.7 based on 
previous studies. NLR was recorded as followed: before surgery (within 15 days prior to RC, 
[NLR1]), postoperatively (within 2 days [NLR2], between 7 and 15 days after RC before 
discharge [NLR3], few days before the evidence of recurrence or last available follow up [NLR4]. 
∆NLR was calculated as the difference between NLR2 and NLR1 (NLR∆1) and between NLR 2 
and NLR3 (NLR∆2). Tumour stage, lymphovascular invasion (LVI) and lymph node involvement 
were collected. Cancer-specific mortality (CSM), all-cause mortality (ACM) and recurrence-free 
survival (RFS) were estimated using the Kaplan-Meier method and compared using the log-rank 
test. Univariable and multivariate logistic regression and Cox proportional hazard models were 
used to analyze the association of NLR with extravesical disease, LVI, lymph node involvement, 
recurrence of disease and mortality 
Results: During a follow up of 15.9 months, 45 (34.1%) patients had a recurrence of UBC, 60 
(45.4%) patients died, 38 (28.8%) of UCB and 22 (16.7%) of other cause. 64 (48.5%) have no 
evidence of disease at follow-up. When assessed by multivariable analysis NLR1 remained 
independently associated with a significantly increased risk of extravescical disease (pT 3-4) [OR: 
1.4, p<0.01] and Lymphovascular invasion [OR: 1.40, p<0.01]. NLR4 was independently 
associated with a significantly increased risk of CSM [HR=1.14, p=0.013]. In a postoperative 
model, NLR3 was found to be an independent predictor of ACM [HR=1.11, 95%, p=0.01]. NLR1 
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was associated with a significantly increased risk of recurrence in the univariable preoperative 
model [HR=1.9, p=0.05] while in the postoperative model, NLR4 remained independently 
associated with a significantly increased risk of recurrence [HR 1.13, p=0.03].  
Conclusions: In patients with UCB treated with RC, NLR is associated with more advanced 
tumour stage, LVI, lymph node metastasis and higher CSM. Furthermore, the variation of NLR 
after surgery might play a role to predict higher ACM and RFS. 
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Introduction 
 
The Neutrofil to Lynfocite ratio in the literature 
The neutrophil-to-lymphocyte ratio (NLR) represents an easily measured, reproducible, and 
inexpensive marker of systemic inflammation. 
It has been hypothesized that the synthesis of inflammatory cytokines triggered by the tumor 
microenvironment alters acute phase reactants and hematologic components, including serum 
neutrophil and lymphocyte counts [1, 2]. 
As part of the tumor microenvironment, neutrophils and lymphocytes both play prominent 
regulatory roles in tumor progression. Furthermore, the NLR is a marker of systemic inflammatory 
response that reflects the balance of the inflammatory system and immune system.  
The NLR has been associated with oncologic outcomes in multiple malignancies, including breast, 
colorectal, lung, liver and gastric [3-6] however, the prognostic role of the neutrophil to lymphocyte 
ratio for urological cancers is still not well defined.  
 
The Neutrofil to Lynfocite ratio in Urothelial bladder cancers (UCB) 
Urothelial bladder cancers (UCB) can be subdivided into two major disease states with different 
implications for clinical management [7, 8]. Non-muscle invasive bladder cancers (NMIBCs) 
correspond to the bulk of cancer incidence. They generally do not pose a significant threat to the 
life of the patient but do invariably recur, necessitating expensive lifelong cystoscopy and local 
resection that generate significant patient discomfort and make NMIBC the most expensive of all 
cancers to clinically manage. Importantly, a fraction of high-grade NIMBCs do progress to become 
invasive, but no tools are available to prospectively identify these tumors, and surgeons must rely 
on their clinical judgement and experience to decide when to offer patients definitive therapy. On 
the other hand, muscle- invasive bladder cancers (MIBCs) are clinically aggressive, and up to 50% 
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of patients die of their disease. For the urothelial carcinoma (TCC), the evaluation of NLR might be 
particularly relevant, as inflammation appears to play a critical role in the genesis, progression, and 
mortality from UCB. Indeed, urothelial carcinoma is one of the few malignancies with a defined 
role for immunotherapy (eg, bacillus Calmette-Guerin (BCG). 
The accurate prediction of the best treatment option (surgery rather than systemic therapies) is a 
pivotal issue for clinicians. The development of novel biomarkers which might enhance the 
selection of the most appropriate candidate to therapies would improve outcomes of urological 
cancers. Again, there are no tools that can be used to distinguish patients with lethal cancers from 
those that can be cured. NLR evaluation could be helpful in the selection of the best candidate to a 
specific therapy, however, the exact role of NLR is still controversial. Current literature differs for 
study design, sample size, patient’s selections, timing of the blood measurements in relation to 
surgery or chemotherapy and NLR kinetics measurements. Thus, there is a need to explore whether 
the prognostic value of NLR is retained, or even increased, when measured not only preoperatively 
but also postoperatively.  
 
Aim of the study 
 
In this study, we evaluated the association of preoperative and postoperative NLR with oncological 
outcomes following RC. Specifically, we assessed the association of NLR with pathological 
variables  as well as its impact as predictor of recurrence-free and cancer-specific survival 
estimates, and all cause mortality.   
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Material and Methods 
 
This is a prospective single-centre single-surgeon cohort of 132 consecutive patients with UCB 
treated with open radical cystectomy (RC) and lymph node dissection between July 2013 and 
December 2016. 
Exclusion criteria of the study were patients with an infection, inflammatory diseases, autoimmune 
diseases, a second primary cancer, splenectomies, a bladder cancer other than the urothelial cancer 
subtype, a hematologic or hepatic disorder with the potential to alter the neutrophil-lymphocyte 
ratio, and missing. 
Clinicopathologic variables recorded included: age, sex, Eastern Cooperative Oncology Group 
(ECOG) performance status, preoperative and postoperative (NLR), body mass index, receipt of 
BCG therapy, clinical tumor stage, radial surgical margin status, pathologic tumor and lymph node 
stages, presence of lymph node involvement (LVI), and receipt of adjuvant chemotherapy. Tumor 
staging followed the American Joint Committee on Cancer/Union Internationale Contre le Cancer 
TNM classification. 
NLR was recorded as followed: 
- before surgery (within 15 days prior to RC, [NLR1]), 
- postoperatively (within 2 days [NLR2], 
- between 7 and 15 days after RC before discharge [NLR3], 
- few days before the evidence of recurrence or last available follow up [NLR4], 
∆NLR was calculated as the difference between NLR2 and NLR1 (NLR∆1) and between NLR 2 
and NLR3 (NLR∆2).  
NLR was analysed both as a continuous variable and as a categorical variable using a cut-off of 2.7 
based on previous studies [9]. 
Postoperative follow-up was at least every 3–4 mo in year 1, every 6 mo in year 2, and annually 
thereafter. Follow-up visits consisted of a physical examination and serum chemistry evaluation. 
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Tumors were staged according to the 2002 TNM classification. Tumor grade was assigned 
according to the 1973 World Health Organization grading system. LVI was defined as the presence 
of nests of tumor cells within an endothelium-lined space [10]. A positive soft-tissue surgical 
margin was defined as the presence of tumor in stained areas of soft tissue in RC specimens [11]. 
Data for categorical variables were presented as number and percentage, and data for continuous 
variables as mean ± SD. Group differences for categorical and continuous variables were analyzed 
using chi-square and Mann-Whitney tests, respectively. 
Recurrence-free survival (RFS, defined as local and/or distant soft tissue recurrence, excluding 
metachronous upper tract and urethral cancers), cancer-specific mortality (CSM) and all-cause 
mortality (ACM) were estimated as the time from RC to event using the Kaplan-Meier method. 
Survival was compared between patients with an NLR <2.7 and ≥2.7 with the log-rank test.  
Univariable and multivariate logistic regression and Cox proportional hazard models were used to 
analyse the association of NLR with extravesical (≥pT3) disease, LVI, lymph node involvement, 
disease recurrence and mortality separately between preoperative and postoperative variables. Entry 
values into the multivariable models were a p-value <0.2. 
 A p value <0.05 was considered statistically significant. Statistical analyses were performed using 
SPSS v. 20 (IBM SPSS Inc., Chicago, IL, USA). 
. 
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 Results 
 
Patient and tumor characteristics are listed in Table 1.   
Median age was 74 years (IQR 68-81years).  Median NLR values were 3 (IQR 2.1-4.2), 8.9 (IQR 
6.2-13), 4.1 (IQR 3-6.2) and 2.3 (IQR 1.7-3) respectively for NLR1, NLR2, NLR3 and NLR4 
(p<0.05). 
Median NLR∆1 and NLR∆2 were respectively 5.7 (2.6-9.1) and 3.8 (1.07-8.10). Extravesical 
disease, LVI and lymph node involvement were found respectively in 57 (43.5%), 63 (49.2%) and 
20 (18.7%) patients. Median follow-up was 15.9 (IQR 7.9-26.0 months). During this timespan, 45 
(34.1%) patients had a recurrence of UBC, 60 (45.4%) patients died, 38 (28.8%) of UCB and 22 
(16.7%) of other cause. 64 (48.5%) have no evidence of disease at follow up. 
A high NLR1 was associated with a bigger tumour size (p<0.01), a greater likelihood of receiving 
intravescical therapy (p=0.04), advanced T stage (p <0.01), lymphovascular invasion (p<0.01) 
positive surgical margin (p = 0.02), a greater likelihood of blood transfusion (p=0.016), recurrence 
of disease (p=0.016) and cancer specific death (p=0.02) (table 2) 
A high NLR2 was associated with an BMI (p=<0.01) and tumor size (p=0.04) (table 3), while a 
high NLR3 seems to have no relation with clinic-pathological characteristics (table 4). 
A high NLR4 was associated with age (p=0.05) advanced T stage (p= 0.01), lymph node 
involvement (p=0.017), positive surgical margin (p=0.03), a greater likelihood of receiving 
adjuvant chemotherapy (p = 0.021), recurrence of disease (p<0.01), and cancer specific death 
(p<0.01) (table 5). 
On survival analysis, when patients were stratified according to NLR 1 with a cut of 2.7, overall 
survival and recurrence-free survival were significantly different (p= 0.042 and p= 0.046), (fig 1 
and 3). When patients were stratified according to NLR 4 with a cut of 2.7, recurrence-free survival 
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was significantly different (p <0.01) (fig 4). No difference in cancer-specific survival was found 
between groups (fig 3).   
When assessed by multivariable analysis, NLR1 remained independently associated with a 
significantly increased risk of extravescical disease (pT 3-4) [OR: 1.41 95% CI 1.11-1.80 p<0.01] 
and lymphovascular invasion [OR: 1.40, 95% CI 1.09-1.83, p<0.01] (Table 6 -8). 
When assessed the association of NLR with CSM, NLR4 was independently associated with a 
significantly increased risk [HR=1.14, 95% CI 1.03-1.24 p=0.013] (table 9). 
At univariable analysis NLR1 was found to be a preoperative predictor for ACM [HR=1.79, 95% 
CI 1.015-3.14, p=0.044] (table 10). 
In the postoperative model, NLR3 was found to be an independent predictor of ACM [HR=1.11, 
95% CI 1.02-1.21, p=0.01] (table 10). NLR1 was associated with a significantly increased risk of 
recurrence in the univariable preoperative model [HR=1.9, 95% CI 1.00-3.65 p=0.05] while in 
the postoperative model, NLR4 remained independently associated with a significantly increased 
risk of recurrence [HR 1.13, 95% CI 1.04-1.23, p=0.03]. 
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Table 1. Overall Patients and tumor Characteristics 
 
 
 
 
 
 
 
 
 
 
 Total (132 patients) 
Age, Median (IQR) 74 (68-81) 
Sex, no. (%) 
Female 
Male 
 
27 (29.5%) 
105 (79.5%) 
BMI, kg/m2 (IQR) 26.5 (23.8-29.8) 
Neutrophil/ Lymphocyte ratio before surgery (NLR1) 2.97 (2.1-4.2) 
Neutrophil/ Lymphocyte ratio immediately after surgery (NLR2) 8.87 (6.19-13.03) 
Neutrophil/ Lymphocyte ratio at discharge (NLR3) 4.06 (2.96-6.24) 
Neutrophil/ Lymphocyte ratio at recurrence (NLR4) 2.29 (1.7-3.06) 
NLR∆1 5.7 (2.6-9.1) 
NLR∆2 3.8 (1.07-8.10) 
ECOG performance status, no. (%) 
0 
1 
2 
3 
 
51 (38.6%) 
58 (43.9%) 
20 (15.2%) 
3 (2.3%) 
Max tumor size 
<=2 cm 
>3 cm 
 
64 (48.5%) 
64 (48.5%) 
Receipt of Intravescical therapy: 
No vescical therapy 
Vescical therapy 
 
108 (82.4) 
23 (17.6) 
Clinical T stage, no. (%) 
<=2 
T3-T4 
 
117 (90) 
13 (10) 
Pathologic T stage, no. (%) 
<=2 
T3-T4 
 
74 (56.5) 
57 (43.5) 
pN stage 
pNx 
pN0 
pN1 
pN2 
 
21 (15.9%) 
87 (65.9%) 
10 (7.6%) 
10 (7.6%) 
Perineural invasion no. (%) 26 (20.3%) 
Lymphovascular invasion, no (%) 63 (49.2%) 
Lymph node involvement, no (%) 20 (18.7%) 
Positive surgical margin, no. (%) 12 (9.1%) 
Blood transfusion 37 (28.2%) 
Receipt of adjuvant therapy*, no. (%) 8 (6.1%) 
Patients with recurrence of disease 45 (34.1) 
Follow up status: 
Death for other cause 
Death for bladder cancer 
Non evidence of disease 
Alive with disease recurrence 
 
22 (16.7) 
38 (28.8) 
64 (48.5) 
8 (6.1) 
Follow up time, months 15.9 (7.9-26.0) 
Time to recurrence 13.8 (5.4-24.2) 
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Table 2. Patients and tumor characteristics according to NLR1 <2.7 and NLR1 ≥2.7  
 
 
NLR1 <2.7  
(before surgery) 
(54 patients) 
NLR1 ≥2.7  
(before surgery) 
(74 patients) 
p 
Age, Median (IQR) 73 (65-79.25) 76 (68-82) 0.09 
Sex, no. (%)  
Female 
Male 
 
9 (16.7) 
45 (83.3) 
 
17 (23.0) 
57 (77) 
0.38 
BMI, kg/m2 (IQR)  27 (24.1-30.0) 25.9 (23.0-29.5) 0.28 
ECOG performance status, no. (%) 
0  
1 
2 
3 
 
22 (40.7) 
26 (48.1) 
5 (9.3) 
1 (1.9) 
 
26 (35.1) 
31 (41.9) 
15 (20.3) 
2 (2.7) 
0.38 
Max tumor size 
<=2 cm 
>3 cm 
 
35 (67.3) 
17 (32.7) 
 
28 (38.9) 
44 (61.1) 
<0.01 
Receipt of Intravescical therapy: 
No vescical therapy 
Vescical therapy 
 
39 (73.6) 
14 (26.4) 
 
65 (87.8) 
9 (12.2) 
0.04 
Clinical T stage, no. (%) 
<=2 
T3-T4 
 
50 (94.3%) 
3 (5.7%) 
 
63 (86.3%) 
10 (13.7%) 
<0.01 
Pathologic T stage, no. (%)  
<=2 
T3-T4 
 
41 (77.4) 
12 (22.6) 
 
31 (41.9) 
43 (58.1) 
<0.01 
pN stage  
pNx 
pN0 
pN1 
pN2 
 
6 (11.3) 
40 (7.5) 
2 (3.8) 
5 (9.4) 
 
15 (21.2) 
43 (60.6) 
8 (11.3) 
5 (7.0) 
0.16 
Perineural invasion no. (%) 9 (17.0) 16 (22.5) 0.44 
Lymphovascular invasion, no (%)  19 (35.8) 43 (60.6) <0.01 
Lymph node involvement, no (%) 7 (14.9) 13 (23.2) 0.28 
Positive surgical margin, no. (%)  1 (1.9%) 10 (13.5) 0.02 
Blood transfusion 9 (17) 27 (36.5) 0.016 
Receipt of adjuvant therapy*, no. (%)  3 (5.7) 5 (6.8) 0.80 
Patients with recurrence of disease 13 (22.4) 32 (43.2) 0.016 
Follow up status: 
 Death for other cause 
 Death for bladder cancer 
 Non evidence of disease 
 Alive with disease recurrence 
 
6 (10.3) 
11 (19.0) 
39 (67.2) 
2 (3.4) 
 
16 (21.6) 
27 (36.5) 
25 (33.8) 
6 (8.1) 
0.02 
Follow up time, months 16.1 (7.3-26.6) 16.1 (8.2-26.4) 0.93 
Time to recurrence 15.9 (5.5-25.6) 12.3 (4.5-22.5) 0.82 
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Table 3. Patients and tumor characteristics according to NLR2 <2.7 and NLR2 ≥2.7  
 
 
NLR2 <2.7  
(immediately after 
surgery) 
(4 patients) 
NLR2 ≥2.7  
(immediately after 
surgery) 
 (123 patients) 
p 
Age, Median (IQR) 82.5 (72-91) 75 (68-81) 0.80 
Sex, no. (%)  
Female 
Male 
 
0 
4 (100) 
 
26 (21.1) 
97 (78.9) 
0.3 
BMI, kg/m2 (IQR)  24 (23.5-24.5) 26.6 (23.6-29.7) <0.01 
ECOG performance status, no. (%) 
0  
1 
2 
3 
 
1 (25) 
3 (75) 
0 
0 
 
47 (38.2) 
53 (43.1) 
20 (16.3) 
3 (2.4) 
0.6 
Max tumor size 
<=2 cm 
>3 cm 
 
4 (100) 
0 
 
57 (47.9) 
62 (52.1) 
0.04 
Receipt of Intravescical therapy: 
No vescical therapy 
Vescical therapy 
 
3 (75) 
1 ( 25) 
 
100 (82) 
22 (18) 
0.75 
Clinical T stage, no. (%) 
<=2 
T3-T4 
 
4 (100) 
0 
 
 
108 (89.3) 
13 (10.7) 
0.48 
Pathologic T stage, no. (%)  
<=2 
T3-T4 
2 (50) 
2 ( 50) 
69 (56.6) 
53 (43.4) 
0.79 
pN stage  
pNx 
pN0 
pN1 
pN2 
 
1 (25) 
2 (50) 
0 
1 (25) 
 
 
19 (16) 
82 (68.9) 
10 (8.4) 
8 (6.7) 
0.47 
Perineural invasion no. (%) 1 (25) 24 (20.2) 0.81 
Lymphovascular invasion, no (%)  2 (50) 60 (50.4) 0.99 
Lymph node involvement, no (%) 1 (33.3) 18 (18) 0.5 
Positive surgical margin, no. (%)  0 12 (9.8) 0.5 
Blood transfusion 1 (25) 34 (27.9) 0.9 
Receipt of adjuvant therapy*, no. (%)  0 7 (5.7) 0.6 
Patients with recurrence of disease 1 (25) 42 (34.1) 0.70 
Follow up status: 
 Death for other cause 
 Death for bladder cancer 
 Non evidence of disease 
 Alive with disease recurrence 
 
2 (50) 
1 (25) 
1 (25) 
0 
 
20 (16.3) 
36 (29.3) 
60 (48.8) 
7 (5.7) 
0.35 
Follow up time, months 15.7 (9.4-26.4) 16.1 (8.1-26.5) 0.19 
Time to recurrence 15.7 (7.9-26.4) 13.8 (13.8-24.8) 0.2 
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Table 4. Patients and tumor characteristics according to NLR3 <2.7 and NLR3 ≥2.7  
 
 
NLR3 <2.7  
(at discharge) 
(25 patients) 
NLR3 ≥2.7  
(at discharge) 
 (104 patients) 
p 
Age, Median (IQR) 73 (63.5-82) 75 (68-81) 0.20 
Sex, no. (%)  
Female 
Male 
 
5 (20) 
20 (80) 
 
22 (21.2) 
82 (78.8) 
0.89 
BMI, kg/m2 (IQR)  24.9 (24-28.1 28 (23.6-29.8) 0.17 
ECOG performance status, no. (%) 
0  
1 
2 
3 
 
7 (28) 
16 (64) 
2 (8) 
0 
 
41 (39.4) 
42 (40.4) 
18 (17.3) 
3 ( 2.9) 
0.17 
Max tumor size 
<=2 cm 
>3 cm 
 
12 (50) 
12 (50) 
 
50 (49.5) 
51 ( 50.5) 
0.96 
Receipt of Intravescical therapy: 
No vescical therapy 
Vescical therapy 
 
19 (76) 
6 (24.0) 
 
86 (83.5) 
17 (16.5) 
0.38 
Clinical T stage, no. (%) 
<=2 
T3-T4 
 
23 (92) 
2 (8) 
 
91 (89.2) 
11(10.8) 
 
0.68 
Pathologic T stage, no. (%)  
<=2 
T3-T4 
13 (52) 
12 ( 48) 
59 (57.3) 
44 (42.7) 
0.63 
pN stage  
pNx 
pN0 
pN1 
pN2 
 
4 (16.7) 
18 (75) 
1 (4.2) 
1 (4.2) 
 
17 (16.8) 
66 (65.3) 
9 (8.9) 
9 (8.9) 
0.71 
Perineural invasion no. (%) 4 (16.7) 22 (21.8) 0.58 
Lymphovascular invasion, no (%)  11 (45.8) 51 (50.5) 0.68 
Lymph node involvement, no (%) 2 (10) 18 (21.4) 0.2 
Positive surgical margin, no. (%)  1 (4) 10 (9.7) 0.36 
Blood transfusion 6 (24) 30 (29.1) 0.60 
Receipt of adjuvant therapy*, no. (%)  1 (4.0) 7 (6.8) 0.6 
Patients with recurrence of disease 10 (40) 35 (33.7) 0.55 
Follow up status: 
 Death for other cause 
 Death for bladder cancer 
 Non evidence of disease 
 Alive with disease recurrence 
 
3 (12.0) 
9 (36.0) 
12 (48.0) 
1 (4.0) 
 
19 (18.3) 
29 (27.9) 
49 (47.1) 
7 (6.7) 
0.76 
Follow up time, months 17.3 (6.7-28.8) 15.9 (8.2-25.9) 0.48 
Time to recurrence 16.7 (5.6-28.0) 12.4 (4.3-22.8) 0.68 
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Table 5. Patients and tumor characteristics according to NLR4 <2.7 and NLR4 ≥2.7  
 
 
NLR4 <2.7  
(at recurrence or last 
follow up) 
 (77 patients) 
NLR4 ≥2.7  
(at recurrence or 
last follow up) 
 (48 patients) 
p 
Age, Median (IQR) 74 (65-81) 76 (69-81) 0.05 
Sex, no. (%)  
Female 
Male 
 
16 (20.8) 
61 (79.2) 
 
10 (20.8) 
38 (79.2) 
0.99 
BMI, kg/m2 (IQR)  27.3 (23.9-29.9) 25.5 (23.4-29.0) 0.25 
ECOG performance status, no. (%) 
0  
1 
2 
3 
 
33 (42.9) 
32 (41.6) 
10 (13.0) 
2 ( 2.6) 
 
14 (29.2) 
24 (50) 
9 (18.8) 
1 (2.1) 
0.45 
Max tumor size 
<=2 cm 
>3 cm 
 
39 (52.7) 
35 ( 47.3) 
 
21 (44.7) 
26 (55.3) 
0.39 
Receipt of Intravescical therapy: 
No vescical therapy 
Vescical therapy 
 
62 (81.6) 
14 (18.4) 
 
41 (85.4) 
7 (14.6) 
0.58 
Clinical T stage, no. (%) 
<=2 
T3-T4 
 
70 (92.1%) 
6 (7.9%) 
 
40 (85.1%) 
7 (14.9%) 
0.22 
Pathologic T stage, no. (%)  
<=2 
T3-T4 
 
51 (67.1) 
25 (32.9) 
 
21 (43.8) 
27 (56.2) 
0.01 
 
pN stage  
pNx 
pN0 
pN1 
pN2 
 
11 (14.9) 
58 (78.4) 
3 (4.1) 
2 (2.7) 
 
9 (19.1) 
26 (55.3) 
5 (10.6) 
7 (14.9) 
0.017 
Perineural invasion no. (%) 15 (20.3) 10 (21.3) 0.89 
Lymphovascular invasion, no (%)  31 (41.9) 27 (57.4) 0.09 
Lymph node involvement, no (%) 5 (7.9) 12 (31.6) <0.01 
Positive surgical margin, no. (%)  4 (5.3) 8 (16.7) 0.03 
Blood transfusion 19 (25) 16 (33.3) 0.31 
Receipt of adjuvant therapy*, no. (%)  1 (1.3) 5 (10.4) 0.021 
Patients with recurrence of disease 15 (19.5) 29 (60.4) <0.01 
Follow up status: 
 Death for other cause 
 Death for bladder cancer 
 Non evidence of disease 
 Alive with disease recurrence 
 
14 (18.2) 
13 (16.9) 
48 (62.3) 
2 8 (2.6) 
 
7 (14.6) 
25 (52.1) 
12 (25) 
4 (8.3) 
<0.01 
Follow up time, months 16.9 (7.5-27.7) 15.9 (7.6-24.8) 0.53 
Time to recurrence 14.9 (6.6-24.6 11.2 (3.5-24.1) 0.96 
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Table 6: univariable and multivariable logistic regression predicting extravescical disease (pT 3-4) 
 Univariable Multivariable 
 OR 95% CI p OR 95% CI p 
Age at surgery 1,00 1.0-1.0 0.73 - - - 
Sex (female vs male)  0.79 0.3-1.8 0.59 - - - 
Intravescical Therapy 1.23 0.51-3.05 0.64 - - - 
cT category 
(cTt2 vs cT<2) 
3.35 0.97-11.5 0.05 3.2 1.00-11.5 0.05 
NLR1 (continuous)  1.44 1.13-1.85 <0.01 1.41 1.11-1.80 <0.01 
NLR1 t2.7 vs 
NLR1<2.7 
4.73 2.15-10.46 <0.01    
 
Table 7: univariable and multivariable logistic regression predicting Lymph node involvement  
 Univariable Multivariable 
 OR 95% CI p OR 95% CI p 
Preoperative 
Age at surgery 0.91 0.86-0.97 0.01 0.91 0.86-0.97 0.01 
Sex (reference: 
female)  
0.62 0.20-1.98 0.42 - - - 
cT category 
(cTt2 vs cT<2) 
1.9 0.69 0.21 3.65 0.42-3.5 0.23 
Intravescical Therapy 
(Yes-No)  
1.01 0.41-3.32 0.98 - - - 
NLR 1 (continuous)  0.90 0.70-1.15 0.42 - - - 
NLR 1 t2.7 vs 
 NLR1 <2.7 
1.72 0.62-4.77 0.29 0.44 0.15-1.25 0.12 
 
  
19 
 
Table 8: Univariable and Multivariable Cox regression predicting Lymphovascular invasion 
 Univariable Multivariable 
 HR 95% CI p OR 95% CI p 
cT category 
(cTt2 vs cT<2 
2.59 0.75-8.89 0.13 2.29 0.65-8.13 0.20 
Age at surgery 1.00 0.96-1.03 0.98 - - - 
Sex (reference: 
female)  
1.17 0.49-2.76 0.72 - - - 
Intravescical Therapy 
(Yes-No) 
0.75 0.30-1.87 0.54 - - - 
NLR1 (continuous)  1.45 1.12-1.88 <0.01 1.41 1.09-1.83 <0.01 
NLR1 t2.7 vs  
NLR1 <2.7 
2.74 1.31-5.74 <0.01 - - - 
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Table 9: Univariable and Multivariable Cox regression predicting cancer specific mortality  
 Univariable Multivariable 
 HR 95% CI p HR 95% CI p 
Preoperative 
Age at surgery 1.04 1.00-1.08 0.04    
Sex (reference: 
female)  
1.06 0.46-2.41 0.89 - - - 
ECOG performance 
status  
1.33 0.84-2.12 0.21 - - - 
Intravescical Therapy 
(Yes-No) 
1.2 0.55-2.65 0.62 - - - 
NLR1(continuous)  1.04 0.85-1.27 0.68 - - - 
NLR1 t2.7 vs NLR1 
<2.7 
1.76 0.87-3.5 0.11    
Postoperative 
Adjuvant 
chemotherapy 
1.13 0.27-4.80 0.86 - - - 
NLR2(continuous) 0.97 0.92-1.02 0.28 - - - 
NLR3(continuous) 1.00 0.87-1.15 0.94 - - - 
NLR ∆ 1 
(continuous) 
0.96 0.92-1.02 0.98 - - - 
NLR ∆ 2 
(continuous) 
1.03 0.98-1.08 0.21 - - - 
NLR 4 (continuous) 1.07 1.04-1.12 <0.01 1.14 1.03-1.24 0.013 
NLR4 t2.7 vs NLR4 
<2.7 
3.12 1.59-6.10 <0.01 - - - 
pT3-4 vs pT<=T2 4.68 2.29-9.56 <0.01 4.34 1.82-10.4 <0.01 
Lymph node invasion  
(pN+ vs pN) 
3.34 1.57-7.10 <0.01 2.05 0.90-4.67 0.08 
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Table 10. Univariable and multivariable Cox regression predicting all cause mortality (ACM) 
 Univariable Multivariable 
 HR 95% CI p HR 95% CI  p 
Preoperative 
Age at surgery 1.05 1.02-1.08 <0.01 1.04 1.00-1.08 0.013 
Sex (reference: 
female)  
0.92 0.49-1.76 0.81 - - - 
Intravescical Therapy 
(Yes-No) 
0.94 0.47-1.87 0.87 - - - 
ECOG  
1 
2 
3 
 
1.9 
1.38 
4.8 
 
0.98-3.70 
0.57-3.33 
9.4-17.5 
<0.01 
0.06 
0.47 
<0.01 
 
1.3 
0.78 
3.0 
 
0.62-2.76 
0.30-2.04 
6.6-12.0 
<0.01 
0.448 
0.62 
<0.01 
NLR1 (continuous)  1.09 0.94-1.27 0.24 - - - 
NLR1 t2.7 vs  
NLR1 <2.7 
1.79 1.015-3.14 0.044 1.65 0.93-2.94 0.08 
Postoperative 
Adjuvant 
chemotherapy 
1.15 0.35-3.75 0.81 - - - 
pT3-4 vs pT<=T2 3.67 2.08-6.47 <0.01 3.9 1.9-7.91 <0.01 
Lymph node invasion  
(pN+ vs pN-) 
2.39 1.24-4.63 <0.01 1.38 0.67-2.38 0.38 
NLR2 (continuous) 0.98 0.94-1.02 0.37 - - - 
NLR 2 t2.7 vs NLR2 
<2.7) 
0.56 0.17-1.8 0.33 - - - 
NLR 3 (continuous) 1.09 1.09-1.17 <0.01 1.11 1.02-1.21 0.01 
NLR 3 (t2.7 vs 
NLR<2.7) 
1.01 0.53-1.91 0.96 - - - 
NLR ∆1 (continuous) 0.97 0.93-1.01 0.20 Not significant * 
NLR ∆2 (continuous) 1.05 1.05-1.09 0.028 Not significant * 
NLR4 (continuous) 1.05 1.01-1.09 <0.01 Not significant * 
NLR4 t2.7 vs  
NLR4 <2.7 
1.99 1.18-3.34 <0.01 Not significant * 
* Separate models with pTstage, Lymph node invasion and separately NLR ∆ 1, NLR ∆ 2, NLR3 or NLR 4. 
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Table 11: Univariable and Multivariable Cox regression predicting recurrence 
 Univariable Multivariable 
 HR 95% CI p HR 95% CI p 
Preoperative 
Age at surgery 1.02 0.98-1.05 0.25 - - - 
Sex (reference: female)  1.20 0.56-2.60 0.67 - - - 
Intravescical Therapy (Yes-No) 1.00 0.47-2.19 0.97 - - - 
ECOG  
1 
2 
3 
 
1.23 
0.78 
3.4 
 
0.63-2.42 
0.29-2.09 
2.76-5.49 
<0.01 
0.54 
0.62 
<0.01 
 
1.07 
0.76 
14.9 
 
0.54-2.11 
0.25-1.84 
1.21-5.69 
<0.01 
0.85 
0.44 
0.01 
cT category 
(cTt2vs cT<2) 
2.8 1.34-5.94 <0.01 2.6 1.21-5.68 0.01 
NLR before surgery 
(continuous)  
1.1 0.89-1.25 0.51 - - - 
NLR1 t2.7 vs NLR1 <2.7 1.9 1.00-3.65 0.05 1.66 0.85-3.25 0.14 
Postoperative 
Adjuvant chemotherapy 1.99 070-5.62 0.2    
pT3-4 vs pT<=T2 4.1 2.18-7.71 <0.01 2.7 1.26-5.79 <0.01 
Lymph node invasion  
(pN+ vs pN) 
4.6 2.23-9.6 <0.01 2.7 1.26-5.79 0.01 
NLR2 (continuous) 1.00 0.96-1.05 0.82 - - - 
NLR2 (t2.7 vs NLR<2.7) 1.46 0.20-10.68 0.70 - - - 
NLR 3 (continuous) 0.99 0.91-1.09 0.95 - - - 
NLR 3 t2.7 vs NLR3 <2.7) 0.89 0.44-1.80 0.75 - - - 
NLR ∆ 1 (continuous) 0.99 0.95-1.04 0.87 - - - 
NLR ∆ 2 (continuous) 1.00 0.96-1.04 0.97 - - - 
NLR 4 (continue) 1.04 1.01-1.07 <0.01 1.13 1.04-1.23 0.03 
NLR4 t2.7 vs NLR4 <2.7 3.7 1.97-7.06 <0.01 - - - 
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Fig1. Overall Free survival for NLR 1<2.7 (blue) and NLR1 ≥ 2.7 (green).  
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Fig 2. Cancer specific free survival for NLR 1<2.7 (blue) and NLR1 ≥ 2.7 (green) 
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Fig 3. Recurrence free survival for NLR4 <2.7 (blue) and NLR4 ≥ 2.7 (green) 
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Fig 4. Recurrence free survival for NLR 1<2.7 (blue) and NLR1 ≥ 2.7 (green) 
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Discussion 
 
In this cohort of patients with UCB undergoing RC with middle term postoperative follow-up, we 
found that preoperative and postoperative NLR were associated with advanced pathologic stage at 
the time of cystectomy, lymphovascular invasion as well as increased risk for disease recurrence, 
CSM, and ACM. These findings remained significant after controlling for clinicopathologic 
features, suggesting an independent association of preoperative and postoperative NLR with these 
adverse outcomes. Interestingly, our results are in line with privies studies (table 12). 
In a study that included 899 patients from a single institution, Viers et al [9] showed that a high 
NLR is associated with a higher risk of extravesical tumor extension (p = 0.03) and lymph node 
metastasis (p = 0.02). They also found that with each unit increase in the NLR, the relative risk of 
death from all causes and from UCB increased by 3% and 4%, respectively.  
Krane et al [12]found that an increase in NLR in conjunction with hypoalbuminemia was associated 
with a greater risk of extravesical disease and worse OS and CSS in a cohort of 68 patients. 
However, 15% of their population received neoadjuvant chemotherapy, which may have affected 
subsequent preoperative NLR values.  
Gondo et al [13] stratified their cohort into risk categories according to tumor size (<3 vs 3 cm), 
presence of hydronephrosis, hemoglobin level ( 11.5 g/dl vs >11.5 g/dl), and NLR (<2.5 vs 2.5). 
The 5-yr survival rates in the low-, intermediate-, and high-risk groups were 78.2%, 60.7%, and 
25.9%, respectively. In multivariate analysis, NLR was an independent prognostic factor for CSS 
(HR 1.95, 95% CI 1.04–3.66). Beyond prognostication in RC patients, NLR may also be useful in 
identifying patients with non–muscle- invasive UCB who would benefit from early RC.  
In a recent study of 424 non–muscle-invasive UCB patients, those with NLR 3 had similar survival 
rates compared to those treated for muscle-invasive UCB [14]. 
Lucca et al in a multicenter study with 4061 patients found that NLR ≥2.7 was associated with 
advanced pathological tumor stages (p< 0.001), lymph node involvement (p< 0.001), 
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lymphovascular invasion (p= 0.008), and positive soft tissue surgical margins (p= 0.001). 
Furthermore, in their study found an indipendent association with both OS (HR 1.11, 95% [CI] 
1.01–1.22; p = 0.029) and cancer-specific survival (CSS) (HR 1.21, 95% CI 1.07–1.37, p = 0.003) 
[15]. 
Other studies evaluated the predictive ability of NLR for OS, CSS and PFS also in smaller cohort of 
patients [16-27]. Only few studies were unable to demonstrate the predictive ability of NLR for OS 
and CSS [21, 28]. Interestingly, a few paper valuated the NLR kinetics in the prediction of 
oncological outcomes, as also shown by the present study [9, 24]. 
Unfortunately, available literature empirically used a differed NLR cutoff, ranging between 2.5 to 
3.89 making results not always comparable. 
Limitations of available literature are also an unclear definition for the timing of the blood test for 
the NLR count before of after surgery. Indeed, this uncertainty are unclear in more than the 70% of 
the available literature. Furthermore, inclusion criteria are different, also in terms of tumor stage 
(local tumor vs advanced and metastatinc patients). 
Although evidence suggest a role of NLR as a prognostic marker in all the BC tumor stage, the 
biological explanation is complex and yet to be elucidated. 
A high NLR reflects both a heightened neutrophil-dependent inflammatory reaction and a 
decreased, lymphocyte-mediated, antitumor immune response. Both of these factors may contribute 
to aggressive tumor biology, cancer progression, and poor prognosis [5, 29]. For example, 
circulating neutrophils have been shown to produce cytokines, such as tumor necrosis factor, 
interleukin (IL)-1, and IL-6, and to secrete the pro-angiogenic vascular endothelial growth factor 
[30]. Furthermore, a relative lymphocytopenia may reflect a lower count of CD4+ T-helper 
lymphocytes, resulting in a suboptimal lymphocyte- mediated immune response to malignancy. 
Thus, the NLR may reflect the combined prognostic information of these two processes and be a 
stronger predictor.  
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We recognize that our study has several limitations.  There are a relatively limited number of 
patients from a single institution with a intermediate follow-up duration. Unfortunately, 
perioperative transfusion, drugs, and courses of neoadjuvant chemotherapy were not included. 
Furthermore, inflammation-based scores, like the NLR, consist of parameters that can be affected 
by infection, chronic disease, and other similar factors not necessarily associated with cancer. 
Although the influence of confounding factors may be minimal in this series of surgical candidates 
who had good performance status and normal body temperature, we were unable to preclude these 
aspects. Data of C-reactive protein-levels as well as proinflammatory cytokines were not available. 
Thus, further prospective, well-controlled clinical studies are needed to confirm if hematologic 
parameters and cytokines are an end result of tumour growth and an underlying cause of mortality.  
We acknowledge the relatively arbitrary cut point used for the Kaplan-Meier analyses in our study 
based on privies literature; nevertheless, this threshold allows our data to be contextualized in light 
of previously published analyses, which, likewise, dichotomized NLR.  
It is unclear whether our findings in patients undergoing RC are generalizable to all bladder cancer 
patients. Further studies are thus warranted in patients with low-intermediate risk NMIBC or 
different histology subtype.  
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Conclusions 
 
In patients with UCB treated with RC, a high preoperative NLR is associated with more advanced 
tumor stages, lymph node involvement, and worse survival. 
Identifying patients at higher risk for recurrence may help develop additional therapies to surgery 
(like neoadjuvant or adjuvant therapies) to improve survival outcomes or establish individualised 
follow-up protocols.  
Future investigations into these relationships, including measuring proinflammatory cytokines, may 
provide further insight into the carcinogenesis and progression to extravesical or systemic disease. 
These provide interesting and potentially targetable areas for future systemic therapies. 
Advantages of NLR as a prognostic biomarker are its availability and low cost. Thus, for the future, 
it may be useful in preoperative patient risk stratification, including consideration for clinical trial 
enrolment, patients counselling, predictions models and clinical decision-making for more 
extensive surgery (like more extensive lymph node dissection) and/or perioperative chemo- or 
radio-therapy. 
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